EP0370989A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Human vascular permeability factor
Assignee: Genentech Inc
•
Filing: 1989-11-20
•
Granted: —
•
Expires: 2009-11-20
Abstract
Abstract A cDNA having a base sequence for human vascular permeability factor has been cloned and characterized and the amino acid sequence of the human vascular permeability factor protein has been determined.
Inventors
- 👤 Pamela Jean Keck
- 👤 Joseph Feder
- 👤 Daniel Thomas Connolly
- 👤 Jitka Vera Olander
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 18:54
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/24; C07K14/00; C07K14/435; C07K14/52
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
12 words
Human vascular permeability factor having an amino acid sequence substantially as follows:
Claim 2
Dependent Claim
12 words
Human vascular permeability factor having an amino acid sequence substantially as follows:
Claim 3
Dependent Claim
15 words
Human vascular permeability factor of.Claim 1 which is N-glycosylated at amino acid residue Asn 75.
Claim 4
Dependent Claim
10 words
Human vascular permeability factor of Claim 1 which is non-glycosylated.
Claim 5
Dependent Claim
16 words
Human vascular permeability factor of Claim 1 including a signal sequence at the N-terminus as follows:
Claim 6
Dependent Claim
14 words
The cDNA of human vascular permeability factor including a nucleotide sequence substantially as follows:
Claim 7
Dependent Claim
14 words
The cDNA of human vascular permeability factor including a nucleotide sequence substantially as follows:
Claim 8
Dependent Claim
2 words
Plasmid hVPF/pUC9.
Claim 9
Dependent Claim
2 words
Plasmid hVPF/pUC9.
Claim 10
Dependent Claim
17 words
Human vascular permeability factor cDNA clone VPF-4 of about 3.5 kb including the cDNA of Claim 5.
Claim 11
Dependent Claim
15 words
Mammalian cells transfected with a vector containing the cDNA sequence for human vascular permeability factor.
Claim 12
Dependent Claim
15 words
Mammalian cells transfected with a vector containing the cDNA sequence for human vascular permeability factor.
Claim 13
Dependent Claim
16 words
C-127 mouse cells transfected with a vector containing the cDNA sequence for human vascular permeability factor.
Claim 14
Dependent Claim
16 words
C-127 mouse cells transfected with a vector containing the cDNA sequence for human vascular permeability factor.
Claim 15
Dependent Claim
59 words
Method for the production of human vascular permeability factor in vitro comprising growing cells derived from the human histiocytic lymphoma cell line U-937 in nutrient culture medium at about 35° to 38 C for a sufficient time to elaborate vascular permeability factor and isolating the resulting vascular permeability factor from the spent cells or the cell culture conditioned medium.
Claim 16
Dependent Claim
59 words
Method for the production of human vascular permeability factor in vitro comprising growing cells derived from the human histiocytic lymphoma cell line U-937 in nutrient culture medium at about 35° to 38 C for a sufficient time to elaborate vascular permeability factor and isolating the resulting vascular permeability factor from the spent cells or the cell culture conditioned medium.
Claim 17
Dependent Claim
20 words
The method of Claim 10 in which the vascular permeability factor is isolated from the cell culture conditioned medium by
Claim 18
Dependent Claim
39 words
(a) cation exchange chromatography of said conditoned cell culture medium; (b) metal affinity chromatography of the VPF active fractions from said cation exchange chromatography; and (c) reverse phase HPLC of the active VPF fractions from said method affinity chromatography.
Claim 19
Dependent Claim
39 words
(a) cation exchange chromatography of said conditoned cell culture medium; (b) metal affinity chromatography of the VPF active fractions from said cation exchange chromatography; and (c) reverse phase HPLC of the active VPF fractions from said method affinity chromatography.
Claim 20
Dependent Claim
13 words
The method of Claim 10 in which the nutrient culture medium is serum-free.
Claim 21
Dependent Claim
52 words
The method of Claim 10 in which the cation exchange chromatography is carried out with a column of S-Sepharose Fast Flow cation exchange, the metal affinity chromatography is carried out with a copper/immunodiacetic acid (IDA)/Sepharose column, and the reverse phase HPLC is carried out with a C 18 reverse phase HPLC column.
Claim 22
Dependent Claim
28 words
A human vascular permeability factor having a molecular weight of about 34 to 42 kDa as determined by non-reduced SDS-PAGE and an N-terminal amino acid sequence as follows:
Claim 23
Dependent Claim
28 words
A human vascular permeability factor having a molecular weight of about 34 to 42 kDa as determined by non-reduced SDS-PAGE and an N-terminal amino acid sequence as follows:
Claim 24
Dependent Claim
57 words
The human VPF of Claim 14 containing the following internal sequences: (a) (Gln)Gln Gin Lys Pro, (b) (Arg)Gln Glu Gln Arg(Pro Lys), (c) Phe Met Asp Val Tyr Gin Arg(Arg), (d) lie Phe Lys Pro Ser Cys Val Pro Leu Met Arg, and (e) Val Asp Ile Phe Gin Glu Tyr Pro Asp Glu Ile Glu Tyr.
Claim 25
Dependent Claim
10 words
The human VPF produced by the method of Claim 10.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.